Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Anaphylactoid reactions" patented technology

Dry powder formulations of epinephrine and associated methods

ActiveUS12678404B2Anaphylactoid reactionsBlood flow
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
Owner:BELHAVEN BIOPHARMA INC

Dry powder formulations of epinephrine and associated methods

ActiveUS12661315B2Organic active ingredientsPowder deliveryAnaphylactoid reactionsBlood flow
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
Owner:BELHAVEN BIOPHARMA INC

A luminescent cell for rapid detection of drug allergy and / or allergic reaction and its construction method and application

ActiveCN121574936BAnaphylactoid reactionsDrug allergy
The application discloses a luminescent cell for rapidly detecting drug allergy and / or allergic reaction, and a construction method and application thereof, and relates to the technical field of biotechnology.The construction method comprises the following steps: transforming a myeloid-related cell with a recombinant vector containing a marker gene and an H_HEXA gene promoter to obtain a recombinant cell; and the recombinant cell is the luminescent cell.The application is characterized in that the H_HEXA gene promoter is recombined with the marker gene, and then is transformed into the myeloid-related cell, and the specific activation characteristics of the H_HEXA gene in the allergic reaction / allergic reaction are utilized, so that the occurrence of the allergic reaction or the allergic reaction can be directly reflected through a marker signal.The luminescent cell has good stability, is suitable for drug allergy, allergic reaction risk assessment, environmental sample analysis and other scenes, and provides an efficient, sensitive and convenient technical tool for clinical rapid diagnosis, new drug research and development and scientific research exploration, and can significantly reduce detection cost and operation threshold.
Owner:NAT INST FOR FOOD & DRUG CONTROL